Skip to content

Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting

The Effectiveness of Preoperative Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting After Total Knee Replacement in Hemophilia A

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05636163
Enrollment
120
Registered
2022-12-05
Start date
2022-12-15
Completion date
2023-02-20
Last updated
2022-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Keywords

Neutrophil, Lymphocyte, Platelet, Hemophilia, Post-operative nausea and vomiting

Brief summary

By comparing the incidence of PONV, the dosage of postoperative antiemetic drugs, the postoperative VAS score and the utilization rate of PCIA of hemophilia A patients in the NLR≥2 and NLR\<2 groups, investigators could find out the high value in the diagnosis of hemophilia A, which is helpful to guide the clinical diagnosis and treatment of hemophilia A.

Detailed description

Hemophilia arthropathy is a debilitating complication of hemophilia that occurs primarily in severe forms with recurrent spontaneous intra-articular hemorrhage, with the knee being the most commonly affected joint. Currently, total knee arthroplasty is the standard treatment for end-stage hemophilic arthropathy. Due to the special disease of hemophilia, general anesthesia is often chosen as the preferred anesthesia method, and the risk of bleeding is lower than that of neuraxial anesthesia. However, 20 to 30 percent of surgical patients suffer from post-operative nausea and vomiting after general anesthesia. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio have been suggested as parameters for the diagnosis and follow-up of inflammatory diseases, and inflammation has been found to increase the risk of PONV. However, for patients with hemophilia, no information is currently available on the relationship between the two. In this study, investigators intend to retrospectively analyze the clinical data of patients with hemophilia A in our hospital, explore the clinical value of preoperative NLR and PLR in predicting nausea and vomiting after TKA.

Interventions

None listed

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. The patients with hemophilia A undergoing unilateral total knee arthroplasty. 2. The age of the patients ranged from 18 to 70 years. 3. American Society of Anesthesiologists is graded as I\ III 4. No history of mental illness 5. No history of antiemetic and anticholinergic drugs. 6. No history of serious gastrointestinal diseases.

Exclusion criteria

1. Patients who have received long-term steroid treatment 2. Patients who need more than 2.5 mg neostigmine to reverse muscle relaxants 3. Patients with previous malignant tumor, malabsorption, morbid obesity, hypogonadism, thyroid and parathyroid diseases and autoimmune diseases.

Design outcomes

Primary

MeasureTime frameDescription
Incidence of PONV in patients with hemophilia A receiving general anesthesia orders for knee arthroplastyup to 24 hours after surgeryPONV was defined as the onset of nausea or vomiting within 24 hours after surgery

Secondary

MeasureTime frameDescription
The amount of postoperative antiemeticsup to 24 hours after surgeryantiemetics includes ondansetron, metoclopramide, dexamethasone
VAS score after returning to the wardimmediately after returning to the wardpostoperative pain can be evaluated using the visual analogue scale (0-10 score, 0: no pain, 10: worst imaginable pain).
Usage of PCIAup to 24 hours after surgerythe use of postoperative patient controlled intravenous analgesia

Countries

China

Contacts

Primary ContactYuelan Wang
wyldgf@163.com15953105780

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026